Challenging Domestic Pharmaceutical Business Environment Due to Drug Price Revisions
First written in FY2017-Q1. 15 of 32 entries say "Worsened", first in FY2017-Q3. Latest entry: FY2026.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
13 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「The domestic prescription pharmaceutical industry is operating in an increasingly challenging business environment as ongoing measures to contain medical costs, including drug price revisions, continue to be implemented.」
It reconfirms that the domestic pharmaceutical business environment has become increasingly challenging due to ongoing measures to contain medical costs, including the April 2025 drug price revision. - FY2026-H1WorsenedAnnual report
「The domestic prescription pharmaceutical industry faces an increasingly challenging business environment due to ongoing healthcare cost containment measures, including the April 2025 drug price revision.」
It states that the domestic pharmaceutical business environment has become increasingly challenging due to the April 2025 drug price revision and ongoing measures to contain medical costs. - FY2025-H1WorsenedAnnual report
「During the current interim consolidated accounting period, Japan’s prescription pharmaceutical industry faced an increasingly challenging environment due to the continued promotion of measures to contain healthcare costs, including the drug-price revision implemented in April 2024, and the prescription pharmaceutical market’s growth rate remained flat.」
The company stated that the April 2024 drug price revision had made the domestic pharmaceutical business environment more challenging as a result of healthcare cost containment measures. - FY2024RestatedAnnual report
「The environment surrounding the domestic prescription pharmaceutical business is becoming increasingly challenging due to ongoing measures, including drug price revisions, to contain drug costs.」
The challenging business environment for Japan’s pharmaceutical business resulting from drug-price revisions and other measures to contain drug costs continues to be described. - FY2024-Q3WorsenedAnnual report
「The environment surrounding the domestic prescription pharmaceutical business is becoming increasingly challenging due to ongoing measures, including drug price revisions, to contain drug costs.」
The company reconfirmed the challenging business environment resulting from drug price revisions and other factors. The market growth rate also declined from the mid-single-digit level in the previous quarter to the low single-digit level. - FY2024-Q2MitigatedAnnual report
「During the first 2 quarters of the fiscal year, the domestic prescription pharmaceutical industry implemented a mid-year drug price revision in April 2023. However, following the reclassification of COVID-19 as a Class 5 infectious disease under the Infectious Diseases Control Law, patients' visit patterns recovered to pre-pandemic levels, and the prescription pharmaceutical market recorded a mid-single-digit growth rate.」
Although the mid-year revision was implemented in April 2023, the market recorded mid-single-digit growth as patient visits recovered, improving from the previous low single-digit growth in the low range. - FY2024-Q1WorsenedAnnual report
「During the first quarter of the fiscal year, the domestic prescription pharmaceutical industry implemented a mid-year drug price revision in April 2023. However, as patients' visit patterns recovered to pre-COVID-19 levels, the prescription pharmaceutical market recorded a low single-digit growth rate in the low range.」
The company continued to state that the domestic prescription pharmaceutical business environment was becoming more challenging due to the mid-year drug price revision implemented in April 2023 and other factors. Meanwhile, the market recorded low single-digit growth in the low range as patient visits recovered. - FY2023-Q3WorsenedAnnual report
「Meanwhile, the business environment is expected to become increasingly challenging as implementation of a mid-year drug price revision in fiscal 2023 has been approved as part of reform of the drug pricing system.」
The company described an outlook for an increasingly challenging business environment surrounding drug pricing system reform following the decision to implement a mid-year drug price revision in fiscal 2023. - FY2023-Q1MitigatedAnnual report
「Although a drug price revision was implemented in April 2022 in line with the basic policies for reform of the drug pricing system, patients' visit patterns were returning to normal after being affected by COVID-19, and the market remained flat.」
While the challenging effects of the April 2022 drug price revision continued, the market improved from low growth to flat growth as patients' visit patterns returned to normal. - FY2022-Q3RestatedAnnual report
「During the first 3 quarters of the fiscal year, the domestic pharmaceutical industry was affected by the April 2021 drug price revision implemented in line with the basic policies for reform of the drug pricing system and reduced patient visits due to COVID-19, while the prescription pharmaceutical market recorded a low single-digit growth rate in the low range.」
While the effects of the April 2021 drug price revision and reduced patient visits due to COVID-19 continued, the prescription pharmaceutical market recorded a low single-digit growth rate in the low range. - FY2022-Q2MitigatedAnnual report
「Although affected by the April 2021 drug price revision implemented in line with the basic policies for reform of the drug pricing system and reduced patient visits due to COVID-19, the prescription pharmaceutical market recorded low single-digit growth in the low range.」
While the effects of the drug price revision and reduced patient visits continued, the prescription pharmaceutical market recorded low single-digit growth in the low range, representing an improvement in wording from the low level reported for the previous quarter. - FY2022-Q1WorsenedAnnual report
「During the first quarter of the fiscal year, the domestic prescription pharmaceutical industry market remained low, affected by the April 2021 drug price revision implemented in line with the basic policies for reform of the drug pricing system and reduced patient visits due to COVID-19, among other factors.」
The company continued to describe a challenging environment in which the market remained low, following existing drug cost containment measures and reduced patient visits, as well as the April 2021 drug price revision. - FY2021-Q3RestatedAnnual report
「During the period under review, Japan’s pharmaceutical industry continued to face a challenging business environment due to the implementation of drug-price revisions following the consumption-tax increase (October 2019; industry average: 2.40%), drug-price revisions in line with reforms to the drug-pricing system (April 2020; industry average: 4.38%), and the spread of COVID-19.」
The company reconfirmed the challenging market environment resulting from the impact of drug price revisions and reduced patient visits due to COVID-19, among other factors. - FY2021-Q2RestatedAnnual report
「During the period under review, Japan’s pharmaceutical industry remained at a low level due to the implementation of drug-price revisions following the consumption-tax increase (October 2019; industry average: 2.40%), drug-price revisions in line with reforms to the drug-pricing system (April 2020; industry average: 4.38%), and reduced medical consultations resulting from the spread of COVID-19.」
The company reconfirmed the market downturn caused by drug price revisions averaging 2.40% and 4.38% across the industry and reduced patient visits as a challenging business environment. - FY2021-Q1WorsenedAnnual report
「During the fiscal year, the domestic pharmaceutical industry market declined as a result of the drug price revision accompanying the consumption tax increase in October 2019, averaging 2.40% across the industry, the drug price revision implemented under the 2020 drug pricing system reforms in April 2020, averaging 4.38% across the industry, and reduced patient visits due to the spread of COVID-19.」
In addition to the challenging environment created by previous drug pricing system reforms, the 4.38% industry-average drug price revision in April 2020 and reduced patient visits due to COVID-19 combined to produce negative market growth. - FY2020-Q3WorsenedAnnual report
「A drug price revision averaging 2.4% across the industry was implemented in October in connection with the consumption tax increase. In addition, the outline of the next drug pricing system reforms, scheduled for April 2020 to promote drug cost containment, was finalized, and the challenging environment continued.」
A drug price revision averaging 2.4% across the industry was implemented in connection with the consumption tax increase, the outline of the next drug pricing system reforms scheduled for April 2020 was finalized, and the challenging environment continued. - FY2020-Q2WorsenedAnnual report
「The challenging environment continued as a result of drug cost containment policies, including fundamental reform of the drug pricing system and the promotion of generic drug use, against a backdrop of efforts to control social security benefit spending, as well as a drug price revision averaging 2.4% across the industry accompanying the October consumption tax increase. Growth in markets related to the group remained low.」
In addition to existing drug cost containment policies, a drug price revision averaging 2.4% across the industry was implemented in connection with the consumption tax increase, and the challenging market environment continued. - FY2020-Q1RestatedAnnual report
「The domestic pharmaceutical industry continued to face a challenging environment, and the market remained sluggish due to drug cost containment policies, including fundamental reform of the drug pricing system and the promotion of generic drug use, against a backdrop of efforts to control social security benefit spending.」
The company reconfirmed the sluggish performance of the domestic pharmaceutical market as a challenging business environment due to drug cost containment policies, including reform of the drug pricing system. - FY2019RestatedAnnual report
「Market growth remained low due to the fundamental reform of the drug pricing system implemented in April 2018, including a drug price revision averaging 7.5% across the industry.」
The company continued to describe low market growth following the fundamental reform of the drug pricing system in April 2018 and the 7.5% industry-average drug price revision as a challenging business environment. - FY2019-Q3RestatedAnnual report
「During the fiscal year, market growth remained low as a result of the fundamental reform of the drug pricing system implemented in April 2018, including a drug price revision averaging 7.5% across the industry, amid various measures to improve the efficiency of healthcare and drug spending against a backdrop of securing funding for social security spending.」
The company described the challenging environment in which market growth remained low following the fundamental reform of the drug pricing system in April 2018 and the 7.5% industry-average drug price revision. - FY2019-Q2RestatedAnnual report
「During the fiscal year, market growth remained low as a result of the fundamental reform of the drug pricing system implemented in April 2018, including a drug price revision averaging 7.5% across the industry, amid various measures to contain drug and healthcare costs.」
The company continued to describe low market growth following the fundamental reform of the drug pricing system in April 2018 and the 7.5% industry-average drug price revision as a challenging business environment. - FY2019-Q1WorsenedAnnual report
「During the fiscal year, market growth in the domestic pharmaceutical industry turned negative due to the 2018 drug pricing system reforms implemented under the basic policies for fundamental reform, including a drug price revision averaging 7.5% across the industry.」
The 2018 drug pricing system reforms were implemented, and market growth turned negative due to the 7.5% industry-average drug price revision and other factors. - FY2018WorsenedAnnual report
「During the fiscal year, measures to improve the efficiency of healthcare spending and contain drug costs were promoted against a backdrop of securing funding for social security spending, and market growth remained low. In addition, reforms to the drug pricing system were discussed under the basic policies for fundamental reform, and new measures to be implemented from April 2018 were approved.」
Market growth remained low due to measures to contain drug costs, and new drug pricing system measures from April 2018 were approved. - FY2018-Q3WorsenedAnnual report
「During the fiscal year, measures to improve the efficiency of healthcare spending and contain drug costs were promoted against a backdrop of securing funding for social security spending, and market growth remained low. In addition, the impact on sales from the expiration of patents on the group's major products became more pronounced, bringing the group to a point where unprecedented corporate action was required. Active discussions were also held on fundamental reform of the drug pricing system to be implemented from April 2018, and new measures related to the drug pricing system were approved as part of efforts to optimize healthcare spending.」
Market growth remained low due to measures to contain drug costs, and new measures associated with fundamental reform of the drug pricing system from April 2018 were approved. - FY2018-Q2RestatedAnnual report
「During the fiscal year, measures to contain drug costs were promoted against a backdrop of securing funding for social security spending, and market growth remained low.」
The company continued to describe a challenging environment in which measures to contain drug costs, rather than a drug price revision itself, constrained market growth against a backdrop of social security spending. - FY2018-Q1ReframedAnnual report
「During the fiscal year, the domestic pharmaceutical industry saw sluggish market conditions as measures to contain drug costs were implemented against a backdrop of securing funding for social security spending, despite no drug price revision being implemented.」
During the quarter, measures to contain drug costs, rather than a drug price revision itself, were identified as a factor behind the market downturn, against a backdrop of securing funding for social security spending. - FY2017RestatedAnnual report
「The market remained sluggish due to the April 2016 drug price revision and other factors. In addition, specific discussions began under the basic policies formulated in December 2016 for fundamental reform of the drug pricing system, pointing to a potentially challenging business environment in the future」
The company reconfirmed the outlook for a challenging environment due to the impact of drug price revisions and reform of the drug pricing system. - FY2017-Q3WorsenedAnnual report
「During the fiscal year, market growth in the domestic pharmaceutical industry remained sluggish due to the April 2016 drug price revision and other factors. At the same time, while basic policies were announced for fundamental reform of the drug pricing system from April 2017, suggesting an increasingly challenging business environment, measures to accelerate the evaluation of innovation were also discussed.」
In addition to the drug price revision already implemented, fundamental reform of the drug pricing system from April 2017 was announced, strengthening the outlook for a challenging business environment. - FY2017-Q2RestatedAnnual report
「During the fiscal year, the domestic pharmaceutical industry faced a challenging business environment, as market growth remained sluggish due to the April 2016 drug price revision, which reduced prices by an industry average of 7.8% and by the 6% range for 杏林製薬, as well as other reforms to the drug pricing system.」
The company continued to describe a challenging domestic pharmaceutical business environment, including drug price revision rates. - FY2017-Q1First statedAnnual report
「The domestic pharmaceutical industry faced a challenging business environment, with market growth remaining sluggish due in part to the April 2016 drug price revision, which averaged 7.8% for the industry and was in the 6% range for KYORIN Pharmaceutical.」
The April 2016 drug price revision had already been implemented, with a 7.8% industry-average revision and a revision in the 6% range for the Company.